https://www.clinrol.com/study/320
Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer...
Explore safety and dosing of ECI830 alone and with ribociclib and fulvestrant; assess its anti-tumor activity in HR+/HER2- advanced breast cancer.